|
|
|
|
|
Click Here to return To Results
|
|
|
|
Using an intention-to-treat analysis for the combined results of the two parts of the trial at 6 months and 12 months, we found that the global statistic favored the t-PA group (odds ratio for a favorable outcome at 6 months, 1.7; 95 perce nt confidence interval, 1.3 to 2.3; odds ratio at 12 months, 1.7; 95 percent confidence interval, 1.2 to 2.3). The patients treated with t-PA were at least 30 percent more likely to have minimal or no disability at 12 months than were the placebo-treated patients (absolute increase in the proportion with favorable outcome, 11 to 13 percentage points). There was no significant difference in mortality at 12 months between the t-PA group and the placebo group (24 percent vs. 28 percent, P=0.29). There was no interaction between the type of stroke identified at base line and treatment with respect to the long-term response. The rate of recurrent stroke at 12 months was similar in the two groups. During 12 months of follow-up, the patients with acute isch emic stroke who were treated with t-PA within three hours after the onset of symptoms were more likely to have minimal or no disability than the patients given placebo. These results indicate a sustained benefit of t-PA for such patients. |
|
(click to filter results - removes previous filter)
cerebrovascular accident
cerebrovascular accident,acute management of
cerebrovascular accident,prognosis in
cerebrovascular accident,thrombolytic agents in treatment
fibrinolytic agents
prognosis
tissue plasminogen activator,intravenous
treatment of neurologic disorder
|
Click Here to return To Results
|
|